Breeze Holdings Acquisition Corp.

BRZH

Explore Our Financial Data > Companies > Breeze Holdings Acquisition Corp.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	BRZH
CIK	0001817640
SIC	6770
Sector	Finance, Insurance, And Real Estate
Industry Category	Trading
Industry Group	Investment Offices

Contact

Address	955 W. JOHN CARPENTER FWY., STE. 100-929, IRVING, TX, 75039
Website	N/A
Phone	619-500-7747
CEO	J. Douglas Ramsey
Employees	4

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$16.34 million
Net Income	$16.34 million
Net Income to Common	$16.34 million
EPS	$3.58

View All

Balance Sheet

Cash	$403.00
Assets	$3.52 million
Liabilities	$16.76 million
Common Equity	$-16.43 million
Liabilities & Equity	$3.52 million

View All

Cash Flow Statement

Net Income	$16.34 million
Cash From Operating Activities	$-1.47 million
Cash From Investing Activities	$10.45 million
Cash From Financing Activities	$-8.98 million
Change in Cash	$-4,084.00

View All

Calculations

NOPAT	$-1.53 million
EBITDA	$15.88 million
Price to Earnings	$2.51
Price to Book	N/A
ROE	-101.21%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

YD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business combination with Breeze Holdings Acquisition Corp. ("Breeze"), a publicly traded special purpose acquisition company. Beginning August 29, 2025, YD Bio's ordinary shares and warrants will trade on Nasdaq Global Market under the ticker symbols

Article Link

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market ExpansionTrading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market on August 29, 2025, under the ticker symbols “YDES” and “YDESW” TAIWAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovatio

Article Link

Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited

Transaction Expected to Close in the Coming Days Combined Company to be Named YD Bio Limited and Expectedto Trade on Nasdaq Under Ticker Symbol “YDES” IRVING, Texas, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Breeze Holdings Acquisition Corp. (“Breeze”) (OTCQX: BRZH; OTCQB: BRZHR, BRZHW), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business Combination”) with YD Biopharma Limited (“YD Bio

Article Link

Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited

YD Biopharma is a Clinical-Stage Biopharmaceutical Company Focusing on Cancer Prevention Diagnostics and Seeking to Transform the Treatment of a Wide Spectrum of Diseases Pro Forma for the Transaction, Combined Company is Expected to Have an Estimated Enterprise Value of Nearly $700 Million The Proposed Merger is Expected to Close by Early 2025; After Closing, the Combined Company is Expected to be Listed on Nasdaq Capital Market YD Biopharma has Recently Obtained Patents, Technology, and U.S. A

Article Link

Breeze Holdings Acquisition Corp. Provides Update on Trading Status and Potential Business Combination

IRVING, Texas, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Breeze Holdings Acquisition Corp. (OTCQX: BRZH) (“Breeze” or the “Company”), has been informed its application to trade on the OTCQX Best Market has been approved. As a result, the Company’s common stock and warrants under the tickers “BRZH” and “BRZHW,” respectively, have begun trading on the OTCQX, effective today, August 21, 2024. On August 9, 2024, Breeze filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “SEC”

Article Link